Glenmark Pharmaceuticals LtdPharmaceuticalsINE935A01035Consolidated₹2447.40+31.40 (+1.30%)Jun-26
Valuation
Market Cap₹69.07K Cr
TTM PE38.41x
Forward PE43.62x
PEG1.20
Book Value₹372.50
P/B6.57x
TTM EPS₹63.71
Fwd EPS₹56.11
TTM Revenue₹17.74K Cr
TTM PAT₹1.80K Cr
TTM EBITDA₹4.80K Cr
TTM EBIT₹4.18K Cr
Last Qtr PAT₹482.83 Cr
Last Qtr EBITDA₹804.79 Cr
Last Qtr EBIT₹631.62 Cr
Profitability
ROE17.10%
ROCE24.65%
TTM NPM10.14%
TTM EBITDA %27.04%
Curr OPM11.82%
Last OPM7.61%
Curr NPM
Last NPM
Curr EPS₹17.11
Last EPS₹10.68
Balance sheet
Equity₹28.22 Cr
Reserve₹10.48K Cr
Total Debt₹593.53 Cr
D/E0.06x
Interest %11.18%
Curr Interest₹54.00 Cr
Price / range
Close₹2447.40
vs 52W High
vs 52W Low
MA50
MA200
Returns
1D+1.30%
1W+1.17%
1M+6.18%
3M+13.62%
6M+11.93%
1Y+15.99%
2Y+48.77%
3Y+187.68%
5Y+371.70%
Diwali+20.84%
Sector peers — Pharmaceuticals
CompanyCloseMkt CapTTM P/EROE
SUNPHARMA1837.30₹4.41L Cr36.4514.50%
DIVISLAB9375.00₹2.49L Cr85.0617.45%
TORNTPHARM4840.00₹1.84L Cr77.3225.70%
ZYDUSLIFE1160.00₹1.16L Cr25.8516.94%
CIPLA1394.50₹1.13L Cr33.419.75%
LAURUSLABS1954.00₹1.06L Cr96.4520.58%
AUROPHARMA1734.00₹99.77K Cr27.099.79%
DRREDDY1185.00₹98.91K Cr30.638.40%

Financial Results

Quarterly and yearly P&L · YoY % on Revenue, Total Income, Expenditure, EBITDA, EBIT, PBT, Net Profit and EPS

Standalone

16 lines · 6 periods
MetricJun-26Mar-26Dec-25Sep-25Jun-25FY25-26
Revenue2,434.99+1.7%2,146.582,359.941,538.662,394.938,440.10
Other Income115.41307.88109.06285.7669.34772.02
Total Income2,550.40+3.5%2,454.452,468.991,824.422,464.269,212.12
Interest23.2517.9121.9823.4015.4678.75
Expenditure-1,907.30-9.6%-2,193.09-1,945.39-1,798.99-1,739.87-7,677.34
PBDT000000
EBITDA613.26-15.8%31.53495.71-178728.161,077.40
Depreciation-62.32-60.13-59.18-58.93-57.64-235.89
EBIT550.94-17.8%-28.60436.53-236.93670.52841.51
PBT866.10+115.9%-107.40346.53-906.37401.17-266.07
Tax-130.4733.50-64.46167.18-70.9465.27
Equity28.2228.2228.22028.2228.22
OPM33.96-4.3814.04-58.9116.28-2.89
Net Profit735.64+122.8%-73.90282.07-739.19330.23-200.80
NPM28.84-3.0111.42-48.0413.40-2.18
EPS26.07+122.8%-2.6210-26.1911.700

Yearly results

Last 6 financial years · YoY % vs previous FY

Yearly

17 lines · 6 years
MetricFY 25-26FY 24-25FY 23-24FY 22-23FY 21-22FY 20-21
Revenue8,440.10-8.5%9,226.41+16.9%7,891.12-4.0%8,220.66+1.0%8,141.58+7.6%7,567.93
Other Income772.02356.371,168.02985.94614.63396.24
Total Income9,212.12-3.9%9,582.78+5.8%9,059.14-1.6%9,206.60+5.1%8,756.21+9.9%7,964.17
Expenditure-7,677.34-5.9%-7,249.59-1.7%-7,128.73+0.1%-7,138.86-4.2%-6,849.10-12.4%-6,094.31
Interest-78.75-48.73-277.11-206.82-236.04-265.90
PBDT000000
EBITDA1,077.40-52.0%2,244.18+80.7%1,241.66-15.7%1,472.77-12.8%1,688.22-10.7%1,890.34
Depreciation-235.89-218.63-202.16-184.15-159.70-150.82
EBIT841.51-58.5%2,025.55+94.9%1,039.50-19.3%1,288.62-15.7%1,528.52-12.1%1,739.52
PBT-266.07-112.4%2,154.02-69.2%7,000.75+345.4%1,571.87-32.8%2,337.45+20.3%1,943.76
Tax65.27-543.67-1,833.46-363.11-339.66-294.31
Equity28.2228.220000
OPM (%)-2.8922.4877.0017.0027.0024.00
Net Profit-200.80-112.5%1,610.35-68.8%5,167.29+327.5%1,208.77-39.5%1,997.79+21.1%1,649.45
NPM (%)-2.1816.8057.0013.0023.0021.00
EPS (Rs)0-100.0%57.07-68.8%183.13+327.5%42.84-39.5%70.80+21.1%58.46
CEPS057.07183.1242.8470.8058.46

Consolidated

16 lines · 6 periods
MetricJun-26Mar-26Dec-25Sep-25Jun-25FY25-26
Revenue4,018.48+23.1%3,770.593,900.626,046.873,264.4416,982.50
Other Income65.76189.0844.47200.6326.44460.62
Total Income4,084.25+24.1%3,959.673,945.086,247.503,290.8817,443.13
Interest5442.6041.4366.4658.23208.73
Expenditure-3,440.86-19.8%-3,198.50-3,226.74-3,894.98-2,872.07-13,192.30
PBDT000000
EBITDA804.79+38.6%762.60869.762,359.55580.534,572.41
Depreciation-173.17-147.91-154.45-141.20-129.93-573.48
EBIT631.62+40.2%614.69715.312,218.35450.603,998.93
PBT643.39+573.1%387.77534967.4095.581,984.75
Tax-160.56-86.45-130.77-356.97-48.61-622.79
Equity28.2228.220028.2228.22
OPM15.759.7913.5415.482.9011.38
Net Profit482.83+928.0%301.32403.23610.4346.971,361.95
NPM11.827.6110.229.771.437.81
EPS17.11+930.7%10.6814.2921.631.6648.26

Yearly results

Last 6 financial years · YoY % vs previous FY

Yearly

17 lines · 6 years
MetricFY 25-26FY 24-25FY 23-24FY 22-23FY 21-22FY 20-21
Revenue16,982.51+27.5%13,321.74+12.8%11,813.10-9.1%12,990.11+5.6%12,304.90+12.4%10,943.93
Other Income460.62113.72839.99316.79166.6750.22
Total Income17,443.13+29.8%13,435.46+6.2%12,653.09-4.9%13,306.90+6.7%12,471.58+13.4%10,994.15
Expenditure-13,192.30-13.1%-11,663.43+0.4%-11,715.64-0.4%-11,672.59-8.4%-10,769.42-11.5%-9,656.22
Interest-208.73-207.07-515.97-349.58-298.10-353.11
PBDT000000
EBITDA4,572.42+94.5%2,351.39+96.7%1,195.34-47.5%2,278.37-1.8%2,320.30+11.3%2,084.37
Depreciation-573.48-486.01-581.91-611.27-486.72-443.55
EBIT3,998.94+114.4%1,865.38+204.1%613.43-63.2%1,667.10-9.1%1,833.58+11.7%1,640.82
PBT1,984.75+41.8%1,399.21+3733.5%36.50-95.8%868.45-39.7%1,441.25+4.3%1,382.48
Tax-622.79-352.07-1,867.35-491.05-447.60-412.39
Equity28.2228.220000
OPM (%)11.3810.410.296.5311.5612.57
Net Profit1,361.95+30.1%1,047.14+173.0%-1,433.52-479.8%377.40-62.0%993.65+2.4%970.09
NPM (%)7.817.79-11.332.847.978.82
EPS (Rs)48.26+30.0%37.11+169.7%-53.22-605.4%10.53-68.4%33.37-2.9%34.38
CEPS48.2437.10-53.2210.5333.3734.38

Corporate Actions

Dividends, bonus issues, and stock splits

Dividend

19
YearTypeAmountEx-Date
2026Final Dividend2.531 Aug 2026
2026Interim Dividend2.503 Oct 2025
2025Final Dividend2.515 Sep 2025
2024Final Dividend2.513 Sep 2024
2023Final Dividend2.518 Sep 2023
2022Final Dividend2.512 Sep 2022
2021Final Dividend2.508 Sep 2021
2020Final Dividend2.517 Sep 2020
2019Final Dividend219 Sep 2019
2018Final Dividend219 Sep 2018
2017Final Dividend220 Sep 2017
2016Final Dividend203 Aug 2016
2015Final Dividend210 Sep 2015
2014Final Dividend210 Jul 2014
2013Final Dividend218 Jul 2013
2012Final Dividend219 Jul 2012
2011Final Dividend0.428 Jul 2011
2010Final Dividend0.416 Sep 2010
2009Final Dividend0.410 Sep 2009

Bonus

0

No bonus history.

Split

0

No split history.

Loading company dashboard...
Fetching ratios, charts, and peers